MCID: UVT001
MIFTS: 58

Uveitis

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Uveitis

MalaCards integrated aliases for Uveitis:

Name: Uveitis 12 75 59 29 55 44 15 40 17 72

Classifications:

Orphanet: 59  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:13141
MeSH 44 D014605
NCIt 50 C26909
SNOMED-CT 68 75614007
ICD10 33 H20.9
MESH via Orphanet 45 D014605
UMLS via Orphanet 73 C0042164
Orphanet 59 ORPHA98715
UMLS 72 C0042164

Summaries for Uveitis

Disease Ontology : 12 A uveal disease is characterized by inflammation of any of the layers of the uvea of the eye, which includes the iris, ciliary body, and choroid.

MalaCards based summary : Uveitis is related to posterior uveitis and intermediate uveitis. An important gene associated with Uveitis is NOD2 (Nucleotide Binding Oligomerization Domain Containing 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Fluocinolone Acetonide and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include eye, t cells and endothelial, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 75 Uveitis is the inflammation of the uvea, the pigmented layer that lies between the inner retina and the... more...

Related Diseases for Uveitis

Diseases in the Uveitis family:

Autoimmune Uveitis Posterior Uveitis
Intermediate Uveitis Infectious Anterior Uveitis
Anterior Uveitis Infectious Posterior Uveitis
Systemic Diseases with Anterior Uveitis Systemic Diseases with Posterior Uveitis

Diseases related to Uveitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1022)
# Related Disease Score Top Affiliating Genes
1 posterior uveitis 34.3 TNF SAG RBP3 IL2RA IFNG CAPN5
2 intermediate uveitis 33.9 TNF IL2RA IL10 IFNG HLA-B CXCR3
3 fuchs' heterochromic uveitis 33.8 TGFB2 IL2RA
4 anterior uveitis 33.5 IL2RA HLA-B CTLA4 CCL2
5 panuveitis 33.1 TNF SAG RBP3 IL17A IL10 HLA-B
6 macular retinal edema 33.1 ICAM1 CCL2 CAPN5
7 multifocal choroiditis 33.0 TNF IL10
8 vitreoretinopathy, neovascular inflammatory 32.9 TGFB2 CCL2 CAPN5
9 spondyloarthropathy 1 32.9 TNF NOD2 IL17A HLA-B
10 vogt-koyanagi-harada disease 32.6 IL2RA IL17A IL10 HLA-B
11 juvenile rheumatoid arthritis 32.6 TNF IL2RA IL1R1
12 tropical spastic paraparesis 31.8 IL2RA IL17A IL10 IFNG HLA-B CXCR3
13 spondylitis 31.7 TNF NOD2 IL17A HLA-B
14 cytomegalovirus retinitis 31.7 TNF IFNG HLA-B
15 sarcoidosis 1 31.5 TNF NOD2 IL2RA IFNG CXCR3
16 scleritis 31.4 TNF IL4 IFNG
17 toxoplasmosis 31.4 TNF IL4 IL10 IFNG
18 autoimmune uveitis 31.2 TRIB2 TNF SAG RBP3 IL4 IL17A
19 leptospirosis 31.1 TNF IL10 IFNG CCL2
20 crohn's colitis 31.1 TNF NOD2 IFNG
21 conjunctivitis 31.0 IL4 IFNG ICAM1
22 leprosy 3 31.0 TNF NOD2 IL10 IFNG
23 cytomegalovirus infection 31.0 TNF HLA-B CCL2
24 neuritis 30.9 TNF IL4 IFNG CCL2
25 rubella 30.9 TNF IL4 IL10 HLA-B
26 vasculitis 30.9 TNF IFNA2 ICAM1 HLA-B CCL2
27 psoriatic arthritis 30.8 TNF NOD2 IL1A IL17A HLA-B
28 pertussis 30.8 TNF IL1A IL10
29 meningitis 30.8 TNF IL10 IFNG CCL2
30 mumps 30.8 TNF IL2RA IFNG
31 herpes zoster 30.7 IL10 IFNG IFNA2 HLA-B
32 kawasaki disease 30.7 TNF IL10 CCL2
33 reactive arthritis 30.7 TNF IL17A IL10 IFNG HLA-B
34 candidiasis 30.6 IL17A IL10 IFNG
35 immune deficiency disease 30.6 IL4 IL2RA IL1A IL10
36 ulcerative colitis 30.6 TNF NOD2 IL17A IL10 IFNG
37 oligoarticular juvenile idiopathic arthritis 30.6 TNF IL2RA CXCR3
38 temporal arteritis 30.5 TNF IFNG CCL2
39 punctate inner choroidopathy 30.5 TNF IL10
40 spotted fever 30.4 TNF IL10 IFNG
41 drug reaction with eosinophilia and systemic symptoms 30.4 TNF HLA-B
42 connective tissue disease 30.4 TNF IL1A IL10 IFNG
43 peritonitis 30.4 TNF IL10 ICAM1 CCL2
44 stromal keratitis 30.4 TNF IL2RA IL17A CCL2
45 extrapulmonary tuberculosis 30.3 IL10 IFNG CCL2
46 chlamydia 30.3 TNF IL4 IL1A IL10 IFNG
47 arthritis 30.3 TNF NOD2 IL1A IL17A IL10 IFNG
48 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.3 IL17A IL10 IFNG CTLA4
49 keratoconjunctivitis 30.3 TNF IL4 IFNG ICAM1
50 central nervous system vasculitis 30.3 TNF IL17A IFNG

Graphical network of the top 20 diseases related to Uveitis:



Diseases related to Uveitis

Symptoms & Phenotypes for Uveitis

GenomeRNAi Phenotypes related to Uveitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 ICAM1 IL10 IL17A IL1A IL2RA NOD2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 ICAM1 IL10 IL17A IL1A IL2RA NOD2

MGI Mouse Phenotypes related to Uveitis:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 CTLA4 CXCR3 ICAM1 IFNG IL10 IL17A
2 immune system MP:0005387 10.31 CAPN5 CCL2 CTLA4 CXCR3 ICAM1 IFNG
3 hematopoietic system MP:0005397 10.3 CTLA4 CXCR3 ICAM1 IFNG IL10 IL17A
4 growth/size/body region MP:0005378 10.26 CAPN5 ICAM1 IFNG IL10 IL17A IL1R1
5 digestive/alimentary MP:0005381 10.21 CTLA4 ICAM1 IFNG IL10 IL17A IL2RA
6 endocrine/exocrine gland MP:0005379 10.19 CTLA4 ICAM1 IFNG IL10 IL17A IL1R1
7 mortality/aging MP:0010768 10.17 CAPN5 CTLA4 CXCR3 ICAM1 IFNG IL10
8 craniofacial MP:0005382 10.07 IFNG IL10 IL17A IL1R1 IL4 TGFB2
9 integument MP:0010771 9.97 CTLA4 ICAM1 IFNG IL10 IL1A IL1R1
10 respiratory system MP:0005388 9.85 CTLA4 CXCR3 IFNG IL10 IL17A IL1R1
11 neoplasm MP:0002006 9.8 CXCR3 ICAM1 IFNG IL10 IL1A IL1R1
12 skeleton MP:0005390 9.61 CTLA4 IFNG IL10 IL17A IL1R1 IL4
13 vision/eye MP:0005391 9.32 ICAM1 IFNG IL10 IL1R1 IL2RA IL4

Drugs & Therapeutics for Uveitis

Drugs for Uveitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 245)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
2
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
3
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
4
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
5
Difluprednate Approved Phase 4 23674-86-4 443936
6
Fluprednisolone Approved Phase 4 53-34-9
7
tannic acid Approved Phase 4 1401-55-4
8
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
9
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
10
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
11
Timolol Approved Phase 4 26839-75-8 33624 5478
12
Travoprost Approved Phase 4 157283-68-6 5282226
13
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
14
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
15
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
16
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
17
Brinzolamide Approved Phase 4 138890-62-7 68844
18
Certolizumab pegol Approved Phase 4 428863-50-7
19
Dipivefrin Approved Phase 4 52365-63-6 3105
20
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
21
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
22
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
23
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
24
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
25
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
26
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
27
Ranibizumab Approved Phase 4 347396-82-1 459903
28
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
29
Choline Approved, Nutraceutical Phase 4 62-49-7 305
30
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
31 Cloprostenol Vet_approved Phase 4 54276-21-0
32
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
33
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
34
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
35 Cyclosporins Phase 4
36 Calcineurin Inhibitors Phase 4
37 Anticoagulants Phase 4
38 Cathartics Phase 4
39 Laxatives Phase 4
40 Anti-Allergic Agents Phase 4
41 Antihypertensive Agents Phase 4
42 Contraceptive Agents Phase 4
43 Dextrans Phase 4
44 Lubricant Eye Drops Phase 4
45 Luteolytic Agents Phase 4
46 Adrenergic Antagonists Phase 4
47 Adrenergic Agents Phase 4
48 Plasma Substitutes Phase 4
49 Anti-Arrhythmia Agents Phase 4
50 Blood Substitutes Phase 4

Interventional clinical trials:

(show top 50) (show all 398)
# Name Status NCT ID Phase Drugs
1 A Multi-Center, Prospective Single Arm Study to Assess the Efficacy and Safety of RETISERT (Intravitreal Flucinolone Acetonide 0.59mg) in Patients With Refractory Ocular Behcet's Disease Unknown status NCT00720928 Phase 4 flucinolone acetonide
2 The Efficacy of Intravenous Pulses of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease, a Double Blind Pilot Study Unknown status NCT01306955 Phase 4 methylorednisolone
3 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
4 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
5 Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment Completed NCT00543296 Phase 4 0.59 mg Fluocinolone Acetonide implant
6 TAHOE: Sustained InTravitreal DexAmetHasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
7 Prospective Open Label Study of H.P. Acthar Gel Injection in Patients With Active Non-Infectious Uveitis With Associated Glaucoma Thus High Frequency Regional Corticosteroid and Oral Corticosteroids Cause Intolerable Side-Effects Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
8 Proof of Concept Study of the Effectiveness of Ozurdex in Lieu of Oral Corticosteroids for the Control of Active Intermediate and Posterior Uveitis Requiring Immunosuppressive Drug Therapy Completed NCT02049476 Phase 4 Dexamethasone pellet
9 Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis Completed NCT00589628 Phase 4 infliximab;infliximab
10 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed NCT00132691 Phase 4 fluocinolone acetonide intraocular implant;oral corticosteroid with immunosuppressive agents as needed
11 Multi-center, Randomized, Double Masked, Vehicle Controlled Phase IV Study to Compare the Efficacy, Ocular Safety and Tolerability of a Two Day Treatment With Eye Drops (0.5% Prednisolone Acetate, One Drop Four Times Per Day) in Patients With Intraocular Inflammation After Cataract Surgery, Followed by an Open Label Observational Period of 12 Days Completed NCT00170729 Phase 4 Prednisolone acetate
12 Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With Primary Open Angle Glaucoma Completed NCT01978015 Phase 4 travoprost and timolol maleate fixed combination;latanoprost and maleate timolol fixed combination;bimatoprost and timolol maleate fixed combination;dextran and hypromellose
13 Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012 Completed NCT01668004 Phase 4
14 The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients Completed NCT01280110 Phase 4 Hydroxypropylmethylcellulose;Carboxymethylcellulose
15 A Randomized Clinical Trial Comparing the Intraocular Pressure Changes With the Use of Loteprednol and Dexamethasone After Pterygium Surgery Completed NCT00781300 Phase 4 Loteprednol Etabonate 0.5%;Dexamethasone 0.1%
16 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops: Prospective Double-Blind Randomized Study Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
17 Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
18 A Study to Investigate the Safety and Efficacy of Lucentis (Ranibizumab) in Patients With CNV Due to Causes Other Than AMD and in Patients Where Pigment Epithelial Detachments Are the Primary Manifestation of Their AMD. Completed NCT01628354 Phase 4 Ranibizumab
19 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
20 A Multicenter, Open Label Pilot Study to Explore the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis NIPPU Recruiting NCT03656692 Phase 4 Acthar
21 Intra-cameral Penetration and Efficacy of Ganciclovir Following Topical Administration of 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
22 Macular Edema Nepafenac vs. Difluprednate Uveitis Trial Recruiting NCT01939691 Phase 4 Difluprednate;Nepafenac;Prednisolone acetate
23 Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves Recruiting NCT01535768 Phase 4 Aqueous Suppressant Eye Drops
24 Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW) Active, not recruiting NCT03020992 Phase 4 Certolizumab Pegol
25 Open-label, Single-center, Prospective Study on the Efficacy and Safety of Repository Corticotropin Injection (H.P. ACTHAR GEL) in the Treatment of Adults With Non-infectious Retinal Vasculitis Active, not recruiting NCT03066869 Phase 4 H.P. ACTHAR GEL
26 Subtenons Triamcinolone Acetonide Injections for Treatment of Persistent Choroidal Effusions Post Glaucoma Surgery Not yet recruiting NCT02917564 Phase 4 Triamcinolone Acetonide 1 ml of 40 mg/mL suspension
27 Use of Thalidomide in Chronic Uveitis Terminated NCT00314665 Phase 4 Thalidomide
28 Corticosteroid Sparing Effect of Methotrexate in Patients With Sarcoid- Associated Uveitis: A Double Blind, Randomized, Placebo Controlled-study -UVEXATE Terminated NCT00918554 Phase 4 Methotrexate;Placebo
29 Prospective Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis Who Are Not Well Controlled With, or Intolerant of, Topical or Systemic Corticosteroids Terminated NCT02769702 Phase 4 Acthar
30 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema: The COLLIDE Trial Terminated NCT02684084 Phase 4 Ozurdex;Lucentis
31 Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema (CME) Withdrawn NCT02598869 Phase 4 Triamcinolone Acetonide
32 Methotrexate in the Treatment of Axial Spondyloarthritis. A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study. Withdrawn NCT00298012 Phase 4 Methotrexate
33 Randomized Controlled Study to Evaluate the Efficacy of Adalimumab in Patients With Different Forms of Refractory Uveitis Acronym: Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial) Unknown status NCT00348153 Phase 2, Phase 3 Adalimumab
34 The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis Unknown status NCT00012506 Phase 3 TNFR:Fc
35 Phase III Study of Human Bone Marrow-Derived Mesenchymal Stem Cells to Treat AS Unknown status NCT02809781 Phase 2, Phase 3 Etanercept
36 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
37 Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis Completed NCT03097315 Phase 3
38 Study of Difluprednate in the Treatment of Uveitis Completed NCT00501579 Phase 3 Difluprednate;Prednisolone Acetate
39 A Double-Masked, Placebo-Controlled, Multi-Center, Parallel-Group, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Clinically Quiescent Sight Threatening, Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Completed NCT00404742 Phase 3 Placebo;LX211;LX211;LX211
40 A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Completed NCT00404612 Phase 3 Placebo;LX211;LX211;LX211
41 Phase 3 Confirmatory Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Anterior Uveitis (Including Panuveitis). Completed NCT00406887 Phase 3 Difluprednate Ophthalmic Emulsion
42 A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Anterior Uveitis Completed NCT00404885 Phase 3 Placebo;LX211;LX211;LX211
43 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis Completed NCT00333814 Phase 2, Phase 3 Dexamethasone;dexamethasone;Sham injection
44 A Controlled, Multi-center Study of the Utilization and Safety of the MK II Inserter and the Safety of the FAI Insert in Subjects With Non-infectious Uveitis Affecting the Posterior Segment of the Eye Completed NCT02748512 Phase 3 FAI insert
45 A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis Completed NCT01148225 Phase 3 adalimumab
46 A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects With Macular Edema Associated With Non-infectious Uveitis Completed NCT02595398 Phase 3 4mg CLS-TA Suprachoriodal Injection;Sham Procedure
47 Phase 3 Open-Labeled Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Severe Anterior Uveitis (Including Panuveitis). Completed NCT00407056 Phase 3 Difluprednate Ophthalmic Emulsion
48 A Phase 3, Randomized, Double-masked, Vehicle-controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis. Completed NCT03131154 Phase 3 ADX-102 Ophthalmic Solution (0.5%);Vehicle of ADX-102 Ophthalmic Solution
49 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Inactive Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients Completed NCT01124838 Phase 3 Adalimumab;Prednisone;Placebo
50 A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye Completed NCT01358266 Phase 3 DE-109 44 ug;DE-109 440 ug;DE-109 880 ug

Search NIH Clinical Center for Uveitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Atropine
Atropine Sulfate
Azathioprine
Betamethasone
Bupivacaine
Ciclosporin
Cortisone acetate
Cyclophosphamide
Dexamethasone
Fluocinolone acetonide
Methotrexate
Methylatropine nitrate
Methylprednisolone
Prednisolone
Prednisone
Tetracosactide
Triamcinolone

Cochrane evidence based reviews: uveitis

Genetic Tests for Uveitis

Genetic tests related to Uveitis:

# Genetic test Affiliating Genes
1 Uveitis 29

Anatomical Context for Uveitis

MalaCards organs/tissues related to Uveitis:

41
Eye, T Cells, Endothelial, Testes, Retina, Skin, Neutrophil

Publications for Uveitis

Articles related to Uveitis:

(show top 50) (show all 17061)
# Title Authors PMID Year
1
Immune responses to interphotoreceptor retinoid-binding protein and S-antigen in Behcet's patients with uveitis. 9 38
20089879 2010
2
Production of interleukin-17 in Behcet's disease is inhibited by cyclosporin A. 9 38
20508866 2010
3
Successful resolution of pneumonia developed in a patient affected by Crohn's disease, rheumatoid arthritis, myasthenia gravis and recurrent uveitis during concomitant treatment with tumour necrosis factor alpha inhibitors and conventional immunosuppressive drugs. 9 38
19551384 2010
4
Infliximab and anterior optic neuropathy: case report and review of the literature. 9 38
19916016 2010
5
Efficacy of infliximab on the acute attack of uveitis. 9 38
20062906 2010
6
Intravitreal infliximab in experimental endotoxin-induced uveitis. 9 38
19787603 2009
7
Suppression of experimental uveitis by a recombinant adeno-associated virus vector encoding interleukin-1 receptor antagonist. 9 38
19693263 2009
8
Diagnosis of tuberculous uveitis: clinical application of an interferon-gamma release assay. 9 38
19576501 2009
9
Immune response genes in uveitis. 9 38
19657978 2009
10
Cytokine and molecular analyses of intraocular lymphoma. 9 38
19585355 2009
11
Inhibitory effect of Cyclosporin A and corticosteroids on the production of IFN-gamma and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome. 9 38
19200788 2009
12
Cytokine profiles in toxoplasmic and viral uveitis. 9 38
19302012 2009
13
Retinal S-antigen Th1 cell epitope mapping in patients with Behcet's disease. 9 38
18958488 2009
14
Nucleotide oligomerization domain-2 (NOD2)-induced uveitis: dependence on IFN-gamma. 9 38
19098321 2009
15
[Recommendations for tuberculosis screening before and during treatment with tumour necrosis factor inhibitors]. 9 38
19459572 2009
16
Anti-inflammatory role of IL-17 in experimental autoimmune uveitis. 9 38
19234216 2009
17
Serum PEDF levels are decreased in a spontaneous animal model for human autoimmune uveitis. 9 38
19113885 2009
18
Developments in the scientific and clinical understanding of the spondyloarthritides. 9 38
19232062 2009
19
Blau syndrome-related CARD15/NOD2 mutations are not linked to idiopathic uveitis in Spanish patients. 9 38
19822951 2009
20
Evidence for endotoxin as a causative factor for leptospiral uveitis in humans. 9 38
18658094 2008
21
Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. 9 38
19027420 2008
22
Retrospective analysis of children with uveitis treated with infliximab. 9 38
18930672 2008
23
Interphotoreceptor retinoid-binding protein as biomarker in systemic autoimmunity with eye inflictions. 9 38
18266969 2008
24
Lentiviral-vector-mediated expression of murine IL-1 receptor antagonist or IL-10 reduces the severity of endotoxin-induced uveitis. 9 38
18580969 2008
25
TNFalpha-blocking agents or conventional immunosuppressive drugs in the therapy of children with uveitis? - an evidence based approach. 9 38
18949668 2008
26
Interferon-gamma release assays in the diagnosis of tuberculous uveitis. 9 38
18804561 2008
27
[Recent advances in studies of clinical treatment of uveitis]. 9 38
19176129 2008
28
Spotlight on anti-CD25: daclizumab in MS. 9 38
18808743 2008
29
High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. 9 38
18571896 2008
30
Update on biologics in juvenile idiopathic arthritis. 9 38
18698187 2008
31
Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. 9 38
18579762 2008
32
Regression of vasoproliferative tumor with systemic infliximab. 9 38
18717448 2008
33
Mutation screening of the CARD15 gene in sarcoidosis. 9 38
18384487 2008
34
The use of infliximab in ocular inflammation. 9 38
18408083 2008
35
Tumor necrosis factor inhibitors and uveitis: comment on the article by Lim et al. 9 38
18438832 2008
36
Link between tumor necrosis factor inhibitors and onset of uveitis: comment on the article by Lim et al. 9 38
18438831 2008
37
Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al. 9 38
18438848 2008
38
Interferon-gamma assay in tuberculous uveitis. 9 38
18369081 2008
39
NOD2, the gene responsible for familial granulomatous uveitis, in a mouse model of uveitis. 9 38
18385071 2008
40
Antigen-dependent monophasic or recurrent autoimmune uveitis in rats. 9 38
18203685 2008
41
[Association of ocular inflammation and innate immune response]. 9 38
18411715 2008
42
Th1 and Th2 responses on the ocular surface in uveitis identified by CCR4 and CCR5 conjunctival expression. 9 38
18222196 2008
43
Analysis of Crohn's disease-related CARD15 polymorphisms in Spanish patients with idiopathic uveitis. 9 38
18219096 2008
44
Equine recurrent uveitis--a spontaneous horse model of uveitis. 9 38
18421230 2008
45
Cytokine profile in Behçet uveitis. 9 38
19348376 2008
46
[Profile of selected cytokines in various forms of uveitis]. 9 38
19112859 2008
47
TNFalpha blockade in human diseases: an overview of efficacy and safety. 9 38
17916445 2008
48
Labrafil--a new adjuvant for peptide-specific oral tolerance in rat experimental autoimmune uveitis. 9 38
18042397 2008
49
A case report: zoledronic acid-induced anterior uveitis. 9 38
18488162 2008
50
Aqueous humor levels of asymmetric dimethylarginine (ADMA) are positively associated with monocyte chemoattractant protein-1 (MCP-1) in patients with uveitis. 9 38
17591667 2008

Variations for Uveitis

Expression for Uveitis

Search GEO for disease gene expression data for Uveitis.

Pathways for Uveitis

Pathways related to Uveitis according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 TNF NOD2 IL4 IL2RA IL1R1 IL1A
2
Show member pathways
13.93 TNF TGFB2 IL4 IL2RA IL1R1 IL1A
3
Show member pathways
13.75 TNF TGFB2 IL4 IL2RA IL1R1 IL1A
4
Show member pathways
13.6 TNF TGFB2 IL4 IL2RA IL1R1 IL1A
5
Show member pathways
13.5 TNF TGFB2 IL4 IL2RA IL1R1 IL1A
6
Show member pathways
13.38 TNF NOD2 IL4 IL2RA IL1R1 IL1A
7
Show member pathways
13.37 TNF TGFB2 IL4 IL2RA IL1R1 IL1A
8
Show member pathways
13.18 TNF TGFB2 NOD2 IL10 IFNG IFNA2
9
Show member pathways
13.04 TNF TGFB2 IL1R1 IFNA2 ICAM1 HLA-B
10
Show member pathways
12.91 TNF IL4 IL2RA IL1A IL17A IL10
11 12.86 TGFB2 IL4 IL2RA IFNG IFNA2
12
Show member pathways
12.68 TNF IL4 IL2RA IL10 IFNG
13
Show member pathways
12.66 TNF IL4 IL1A IL17A IL10 IFNG
14
Show member pathways
12.65 TNF IL17A IL10 IFNG CCL2
15 12.64 TRIB2 TNF IL4 IL2RA IL17A IL10
16
Show member pathways
12.63 TNF IL4 IFNG IFNA2 ICAM1 HLA-B
17
Show member pathways
12.56 TNF TGFB2 NOD2 IL4 IL2RA IL1R1
18
Show member pathways
12.48 IL4 IL2RA IL10 IFNG IFNA2
19 12.48 TNF TGFB2 IL2RA IL1R1 ICAM1 HLA-B
20
Show member pathways
12.47 IL2RA IL1R1 IL1A CAPN5
21
Show member pathways
12.43 TNF IL4 IFNG ICAM1 CCL2
22
Show member pathways
12.42 TNF IL4 IL17A IFNG CCL2
23
Show member pathways
12.37 TNF TGFB2 IL4 IL1A IL10 IFNG
24
Show member pathways
12.35 NOD2 IL1R1 IL1A CCL2
25
Show member pathways
12.34 TNF IL1R1 IL1A IFNG
26 12.34 TNF TGFB2 NOD2 IL1A IL10 IFNG
27
Show member pathways
12.27 TNF IL1A IFNG IFNA2
28
Show member pathways
12.24 TNF IL4 IL1R1 IFNG
29 12.21 TNF IL1R1 IL1A IFNG ICAM1 CCL2
30 12.17 TNF TGFB2 IL1R1 IL1A IFNG
31
Show member pathways
12.17 TNF TGFB2 IL4 IL2RA IL1A IL17A
32
Show member pathways
12.16 TNF TGFB2 IL1R1 IL17A IL10 IFNG
33 12.15 TNF IL4 IL1R1 IL1A IFNG ICAM1
34 12.11 TNF IL4 IL1A IL17A IL10 ICAM1
35 12.1 TNF IL4 IL2RA IL10 IFNG IFNA2
36
Show member pathways
12.08 TGFB2 IL4 IL2RA IL1R1 IL1A IL17A
37
Show member pathways
12.06 IL4 IL2RA IL1R1 IFNG
38 12.06 TNF NOD2 ICAM1 CCL2
39 12.04 TNF TGFB2 IL1A ICAM1 CCL2
40 12.04 TNF TGFB2 IL1R1 IL10 IFNG
41 12.02 TNF IL4 IL2RA IL1R1 IL1A
42 11.96 IL2RA IL10 IFNG IFNA2
43 11.93 TNF IL1R1 ICAM1
44 11.89 TNF TGFB2 IFNG
45
Show member pathways
11.88 TNF IL4 IL2RA IFNG CTLA4
46 11.86 TNF IL10 IFNG IFNA2
47 11.83 IL4 IFNG ICAM1
48 11.8 TNF TGFB2 IL4 IL17A IL10 IFNG
49 11.79 TNF IL1A IL10
50
Show member pathways
11.78 TNF IL1A IFNG ICAM1

GO Terms for Uveitis

Cellular components related to Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.9 TNF TGFB2 RBP3 IL4 IL1A IL17A
2 cell surface GO:0009986 9.56 TNF NOD2 IL2RA IL1R1 ICAM1 HLA-B
3 external side of plasma membrane GO:0009897 9.17 TNF IL2RA IL1R1 IL17A ICAM1 CXCR3
4 extracellular region GO:0005576 10 TNF TGFB2 RBP3 IL4 IL1R1 IL1A

Biological processes related to Uveitis according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.97 TNF TGFB2 IFNG IFNA2
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 TNF NOD2 ICAM1 CCL2
3 cellular response to interleukin-1 GO:0071347 9.84 IL17A ICAM1 CCL2
4 B cell differentiation GO:0030183 9.83 IL4 IL10 IFNA2
5 regulation of inflammatory response GO:0050727 9.83 TNF NOD2 IL1R1
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 IL4 IFNG IFNA2
7 interferon-gamma-mediated signaling pathway GO:0060333 9.82 IFNG ICAM1 HLA-B
8 cellular response to organic cyclic compound GO:0071407 9.82 TNF NOD2 CCL2
9 cell surface receptor signaling pathway GO:0007166 9.8 SAG IL2RA IL1R1 IFNG IFNA2 CXCR3
10 interleukin-1-mediated signaling pathway GO:0070498 9.79 NOD2 IL1R1 IL1A
11 extrinsic apoptotic signaling pathway GO:0097191 9.77 TNF TGFB2 IFNG
12 positive regulation of nitric oxide biosynthetic process GO:0045429 9.77 TNF IFNG ICAM1
13 cellular response to lipopolysaccharide GO:0071222 9.77 TNF NOD2 IL10 ICAM1 CCL2
14 inflammatory response GO:0006954 9.76 TNF IL1R1 IL1A IL17A IL10 IFNA2
15 negative regulation of T cell proliferation GO:0042130 9.74 IL2RA IL10 CTLA4
16 negative regulation of endothelial cell apoptotic process GO:2000352 9.73 IL4 IL10 ICAM1
17 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.67 NOD2 CCL2
18 positive regulation of cytokine secretion GO:0050715 9.67 TNF IL1A IL10
19 cytokine-mediated signaling pathway GO:0019221 9.65 TNF IL4 IL2RA IL1R1 IL1A IL17A
20 endothelial cell apoptotic process GO:0072577 9.64 TNF IL10
21 positive regulation of MHC class II biosynthetic process GO:0045348 9.63 IL4 IL10
22 positive regulation of osteoclast differentiation GO:0045672 9.63 TNF IL17A IFNG
23 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.62 TNF ICAM1
24 negative regulation of cytokine secretion involved in immune response GO:0002740 9.62 TNF IL10
25 humoral immune response GO:0006959 9.62 TNF IFNG IFNA2 CCL2
26 positive regulation of interleukin-23 production GO:0032747 9.61 IL17A IFNG
27 regulation of regulatory T cell differentiation GO:0045589 9.61 IL2RA IFNG CTLA4
28 type 2 immune response GO:0042092 9.58 IL4 IL10
29 regulation of isotype switching GO:0045191 9.58 IL4 IL10
30 negative regulation of immune response GO:0050777 9.58 TGFB2 IL2RA CTLA4
31 regulation of complement-dependent cytotoxicity GO:1903659 9.55 TGFB2 IL10
32 receptor biosynthetic process GO:0032800 9.54 TNF IL10
33 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.52 TNF IFNG
34 negative regulation of alkaline phosphatase activity GO:0010693 9.51 TNF TGFB2
35 positive regulation of vitamin D biosynthetic process GO:0060557 9.48 TNF IFNG
36 immune response GO:0006955 9.4 TNF IL4 IL2RA IL1R1 IL1A IL17A
37 apoptotic process GO:0006915 10.1 IL2RA IL1A IL17A IFNG IFNA2 CXCR3

Molecular functions related to Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.28 TNF TGFB2 IL4 IL1A IL17A IL10

Sources for Uveitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....